Bladder Urothelial Carcinoma In Situ

subtype

Identifier: CI-CAN-00004633
Entity page: /cancer/bladder-urothelial-carcinoma-in-situ ↗
Edges: 15

Neighbours: 5 drugs10 trials
Drawn: 15 of 15 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Bladder Urothelial Carcinoma In Situ investigated in trials for …INVESTIGATED_IN_TRIALSderived5 of 5
→ investigated in trials for	Gemcitabinesmall molecule 3 trials (2 active) · roll-up of the cancer and its descendants	—	—	Bladder Urothelial Carcinoma In Situ	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 1 trials (0 active) · roll-up of the cancer and its descendants

Bladder Urothelial Carcinoma In Situ studied in …STUDIED_INderived10 of 10
→ studied in	NCT07189793Phase 2 · not yet recruiting Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study · condition mapped ALIAS · 10 trials mapped (4 active)	—	—	Bladder Urothelial Carcinoma In Situ	1	Observed	clinicaltrials	graph →
→ studied in	NCT04164082Phase 2 · active not recruiting Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer · condition mapped ONTOLOGY_EXACT · 10 trials mapped (4 active)	—	—	Bladder Flat Urothelial Carcinoma In Situ	1	Observed	clinicaltrials	graph →
→ studied in	NCT07231809NA · not yet recruiting Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients · condition mapped ALIAS · 10 trials mapped (4 active)	—	—	Bladder Urothelial Carcinoma In Situ	1	Observed	clinicaltrials	graph →
→ studied in	NCT05375903Phase 1 · completed A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) · condition mapped ALIAS · 10 trials mapped (4 active)	—	—	Bladder Urothelial Carcinoma In Situ	1	Observed	clinicaltrials	graph →
→ studied in	NCT04496219Phase 2 · completed Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer · condition mapped ONTOLOGY_EXACT · 10 trials mapped (4 active)	—	—	Bladder Urothelial Carcinoma In Situ	1	Observed	clinicaltrials	graph →
→ studied in	NCT06167356recruiting Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK. · condition mapped ONTOLOGY_EXACT · 10 trials mapped (4 active)	—	—	Bladder Urothelial Carcinoma In Situ	1	Observed	clinicaltrials	graph →
→ studied in	NCT02901548Phase 2 · terminated Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder · condition mapped ALIAS · 10 trials mapped (4 active)	—	—	Bladder Urothelial Carcinoma In Situ	1	Observed	clinicaltrials	graph →
→ studied in	NCT04647981completed Diagnostic Performance Evaluation Study of the Xpert® Bladder Cancer Monitor Test. · condition mapped ONTOLOGY_EXACT · 10 trials mapped (4 active)	—	—	Non-Invasive Bladder Papillary Urothelial Carcinoma, Low Grade	1	Observed	clinicaltrials	graph →
→ studied in	NCT03335059Phase 3 · terminated Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors. · condition mapped ALIAS · 10 trials mapped (4 active)	—	—	Bladder Urothelial Carcinoma In Situ	1	Observed	clinicaltrials	graph →
→ studied in	NCT01304173completed Retrospective Chart Review of Valstar · condition mapped ALIAS · 10 trials mapped (4 active)	—	—	Bladder Urothelial Carcinoma In Situ	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains